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Ora l  P resentat ions  
inflammatory disease, HER2, hormone receptors, tumor grade, 
previous adjuvant chemotherapy, and prior anthracyclines. CON- 
CLUSIONS: Early lymphocyte recovery is an independent out- 
come predictor after HDC in MBC pts receiving a graft with a 
high T-cell content. These observations support the role for the 
immune system in tumor control after transplant, and suggest that 
pre- or post-HDC inmmne strategies targeting post-transplant 
residual disease may prove worthwhile. 
MBC pts Median DFS Median OS % DFS % OS 
Low ALC (_<500/mm 3) 1 yr 2.5 yrs 20% 29% 
High ALC (>500/ram 3 ) 2.3 yrs 4 yrs 33% 42% 
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BONE MARROW DERIVED HESENCHYMAL STEH CELLS : IMPACT ON 
NEOINTESTINAL ENGINEERING 
Gm~dia, C.; Defavia, W.; Smztiago, S.; Tryopl, o~mpoulos, P.; Ruiz, P.; 
Tzakis, A.; Kleiner, G. U*ziversity of 3/fiami School of MediciJ~e, 
Mia~ni, FL. 
The utilization of bone marrow derived stem cells in tissue 
regeneration and repair is progressing at a dramatic pace. Mes- 
enchymal stem cells are bone marrow derived cells that have been 
utilized to generate bone, cardiac and neuronal tissue. Neointesti- 
nal engineering from intestinal epithelial organoid units (IEOU) 
may be a potential alternative therapy to solve the problems of 
acute organ shortage and rejection in intestinal transplantation. 
The use of MSCs in tissue engineering studies has not been well 
described. We designed a protocol to study the potentiality of 
enteric stem cells resident in the intestinal c~Tpt to differentiate 
into intestinal epithelium. The morphological development in the 
neointestine that occurred at the site of IEOU was studied. 
Neonatal DA rats were used to isolate IEOU by collagenase-dis- 
pase digestion. Organoids (100-100,000) were seeded on 
polyglactin polymer and iluplanted into the omentum or the peri- 
toneal wall of an adult syngeneic animal. IEOU developed into 
neointestinal units. [n as early as three weeks, neointestine was 
demonstrated in 40% of peritoneal implants. As low as 500 IEOU 
resulted in 50% implants positive for neointestinal development 
including intestinal villi, goblet, and crypts. Co-culture of lnes- 
enchymal stem eels and IEOU in a trans-well system resulted in 
morphological changes of the MSCs. Four distinctive cytomor- 
phologies were evident on (lay five of cultre. MSCs in the absence 
of [EOU remained predominantly fibroblasts. The results suggest 
that non-hematopoietic stem cells may be usefill in tissue engi- 
neering. 
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ALDEHYDE DEHYDROGENASE IS EXPRESSED BY PRIMITIVE CD34 + 
HEMATOPOIETIC PROGENITORS 
Storms, R,I,V.s; Snf/'ord, RU; ColviJ1, O.t; Rice, H.~; Smith, C.A. ~ 
1. Depm~ment of 3/iedM~ze, Duke Universi O, 3/lediazl Center, D~trham, 
NC; 2. Mq~tt Cancer Center, Tnmpa, FL. 
Hematopoietic progenitors express aldehyde dehydrogenase 
(ALDH) (PNAS 96:0118, 1999). Cells with low orthogonal light 
scatter and high expression of ALDH (SSC 1° ALDH t'F) were iso- 
lated from umbilical cord blood (UCB) stained with a fluorescent 
substrate for ALDH (BODIPY-aminoacetaldehyde, BAAA). In 
the studies below the SSC 1° ALDH b~ ftaction represented 0.98 _+ 
0.03% of the UCB and were 73.3 + 0.6% CD34 +. These repre- 
sented 46.6 + 0.5% of the total CD34 + UCB cells. We now com- 
pare the deveIopmental potential of CD3@ cells ffactionated on 
the basis of their expression of ALDH. In 5 week long-term cul- 
tures (LTC) on AFF024 stroma, the ALDH h~ CD34 + cells con- 
tained 1.75-fold greater LTC than bulk CD34" UCB cells (196 + 
50 CFU/1000 cells versus 110 -+ 32 CFU/I000 cells, respectively, 
n=4). The ALDH~eg CD34 + fraction contained few LTC (21 -+ 14 
CFU/1000 cells). When cultured on AFT024 stroma with Kit lig- 
and (KL), Flt3 ligand (Flt3L) and IL-7 (see Punzel et al. Blood 
93:3750, 1999) all of the CD34 + cell fractions reproducibly gave 
rise to both lymphoid (CD56 +) and myeloid (CD13/CD15 +) prog- 
eny. The generation of CD56 + progeny was enhanced with the 
addition of ILl5. After 4 weeks in culture on AFF024 with KL, 
Flt3L and IL7, the ALDH t'~ CD34 + cells expanded only slightly 
more than the bulk CD34 + cells (3300 _+ I000-fold vs. 2700 _+ 800- 
fold, respectively, n=3). However the secondary LTC content of 
cultures initiated with ALDH br CD34 + UCB remained approxi- 
mately twice that of bulk CD34 + cultures. Cultures initiated with 
ALDHneg CI)34 + cells expanded only I050 _+ 140-fold and con- 
rained few secondary LTC. To monitor transplantable c lls the 
NOD/SC[D model was employed. Multilineage hematopoietic 
engraftment was docmnented in 8 of 10 NOD/SCID mice trans- 
planted with 3000 SSC l'' ALDH b~ UCB cells (median 3.9%, range 
0.2 - 20.8%) and can be achieved with as few as 300 ALDH b~ 
CD34 + cells. These studies indicate that ALDH b~ cells are more 
efficient han bulk CD34 + cells in this modeh In total, these stud 
ies indicate that the ALDH hr CD34 + UCB are enriched for primi- 
tive, lympho myeloid progenitors. 
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THE ROLE OF B-CATENIN IN CHRONIC MYELOGENOUS LEUKEMIC 
COMPARED WITH NORMAL HUMAN HEMATOPOIETIC STEM CELL 
AND HYELOID PROGENITOR EXPANSION 
ffamiesmz, C.H.; Ailles, L.E.; MuijtjelT,r, M.; Weissman, I.L. Hematol- 
ogy~Pathology, StaJ~bvcl University. 
B-catenin, an important do'amstream regnlator of Wnt  sigualing, 
is frequently mutated in epithelial malignancies and plays a key role 
in hematopoietic stem cell self-renewal (T. Reya et al, submitted). 
Although chronic myelogenous leukemia (CML) is believed to arise 
as a consequence of clonal expansion of defective primitive 
hematopoietic progenitors, tire role of hematopoietic stem cell self- 
renewal genes, such asb-catenin, in expansion of the leukemic smm 
ceil pool has not been fully elucidated. Using confocai fluorescence 
microscopy (Zeiss LSM), intranuclear and cytoplasmic b-catenin 
expression was found to be elevated in chronic myelogenous 
leukemic ompared with normal bone marrow mononuclear cells 
and isotype controls. Five colour FACS analysis demonstrated a 
marked expansion of myeloid progenitors in CML samples corn 
pared with normal bone marrow or peripheral blood but equivalent 
numbers of hematopoietic stem cells. Notably, b-catenin expression 
was found to be elevated in CML compared with normal myeloid 
progenitors while b catenin expression was similar in CML and 
normal HSC. Moreover, because b-catenin induced activation of 
stem cell self-renewal has been shown to be mediated by binding of 
b catenin to the transcription factor - LEF/TCF, normal and CML 
HSC and myeloid progenitors were transduced with a lentiviral 
LEF /TCF  GFP vector to assay for intranuclear binding of b- 
catenin to its downstream target. Although normal nd CML HSC 
displayed similar LEF /TCF  levels after 7 to 10 days in culture, 
CML myeloid progenitors demonstrated greater GFP expression 
than their normal counterparts indicative of increased nuclear 
translocation of b-catenin. These experiments suggest that activa- 
tion of the leVnt signaling pathway through over-expression f acti- 
vated b-catenin in myeloid progenitors may enhance their leukemic 
potential perhaps as a result of reacquisition ofself-renewal capacity. 
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INFLUENZA INFECTIONS AFTER STEH CELL TRANSPLANTATION (SCT): 
RISK FACTORS, HORTALITY AND THE EFFECT OF ANTIVIRAL THERAPY 
Nichols, ~'~G.; 'l~thvie, ILA.; Corey, L.; Boeckh, M. P'rogram iJ~ llzfi'c- 
tiOHS Disem'es, Fred HutchiJ~son Cm~cer Research Center, Seattle, ~f~4. 
Background: Community-acquired respiratory viruses such as 
influenza virus (FLU) arc thought o be major causes of nmrbidity 
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and mortality in patients undergoing SCT. Risk factors for acqui- 
sition, progression to lower respiratory tract infection (LRI), and 
the effect of antiviral therapy are unknown. Methods: Virology 
records were reviewed for cases of FLU infection from day of 
transplant until 120 days after SCT over the last 12 FLU seasons. 
Results: From 9/1/89 until 3/31/02, FLU was isolated from 62 of 
4797 SCT recipients (1.3%); 44 were upper respiratory tract 
infections (URI) alone, while 18 developed LRI. In multivariate 
models that adjusted for FLU season, female gender and advanced 
underlying disease were associated with risk for FLU acquisition 
(Table). Among patients with FLU, LRI was more common 
among those with lymphocytes < 100 (Table) and earlier time of 
infection after transplant (median 36 days vs. 6i days, p=0.04). 
Interestingly, patients receiving steroids for graft vs. host disease 
at the time of diagnosis were less likely to develop LRI. Of the 51 
cases that were initially diagnosed as URI, 17 were treated with 
antivirals and 34 received no treatment; 6 (18%) of untreated 
patients developed LRI, while 1/8 (13 %) treated with rimantadine 
and 0/9 treated with neuraminidase inhibitors (NAI) developed 
LRI. FLU shedding was longer in patients treated with > 1 mg/kg 
steroids (mean 15 days vs. 9 days for those receiving < 1 mg/kg); 
NAI (but not rimantidine) decreased shedding after controlling for 
steroid use (P-0.08). FLU-associated eath (mortality within 30 
days of infection) occurred in 6/62 (9.7%); FLU-associated mor- 
tality in LRI cases was 28% (5/18). Multivariate analysis howed 
that FLU LRI was associated with 1-year mortality after adjusting 
for underlying disease, donor type, cell source, CNIV serostams, 
age at transplant, and year of SCT. Conclusions: FLU infection 
early after SCT is relatively uncommon; this *nay be due to an 
aggressive vaccination program. Overall, 29% of FLU infections 
developed lower tract involvement, which was more common ear- 
lier after transplant and in the presence of lymphocytopenia. 
While not a randomized trial (and sample size is small), our data 
suggests that early antiviral therapy (particularly with NAI) may 
prevent progression to pneumonia and decrease FLU shedding. 
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ADOPTIVE TRANSFER OF HCMV PP65 - PEPTIDE LOADED DCS TO 
IMPROVE HCMV-SPECIFIC T CELL RECONSTITUTION FOLLOWING 
ALLOGENEIC STEM CELL TRANSPLANTATION 
Einsele, H.; Grigoleit, G.U.; Loci:fie*', J.; Beck, R.; I'hlnz, L.; Hebm't, 
H. Hematology/Om'ology, Inte~wal MediciJle of T':t bilzge'17, THebingen, 
Ge*w:aT~y. 
Delayed HCMV-specific immunereconstitution f llowing allo- 
geneic stem cell transplantation (allo SCT) leads to increased inci- 
dence of HCMV disease. In HCMV-seropositive patients under- 
going allo-SCT from a HCMV-seronegative donor it can take up 
to more than 18 months until HCMV-specific T-cell reconstitu- 
tion. Dendritic cells (DCs) have been used in several vaccination 
trials to induce antitumor immuni~ in patients with malignancies. 
Thns, in this phase I/II study DCs pulsed with HCMV pp65 
HLA-A2/A1 binding peptides were used to induce HCMV-specif- 
ic immune responses in 9 HCMV-seropositive patients receiving a
SCT from HCMV-seronegative/tmrelated donors. All patients 
were lacking HCMV-speciflc T-cell responses at time of DC-vac- 
cination and had a HCMV infection. Seven patients received > 4 
weeks of antiviral chemotherapy. None of the patients uffered 
frona HCMV disease at time of DC-vaecination. Reconstitution of
HCMV-specific hnmune-responses was assessed by intraccllular 
IFN-g or tetrameric-complexes staining. HCMV infection was 
documented by qPCR and antigenemia assay. Peptide-pulsed DCs 
were injected subcutaneously betv~een day 30 and day 60 post- 
transplant. The DC-vaccinations were well tolerated and none of 
the patients developed GvHD or autoilnmune phenomena follow- 
ing DC-vaccination. Apart from one patient who died due to 
recurrence of his underlying malignancy all patients are alive and 
well a median of 8 months post-vaccination. Complete data are 
available on 5 patients. In 4 of these an increase in the number of 
ltCMVpp65-specific T-cells was detected between 15 and 60 days 
post-vaccination. None of these 5 patients howed a reactivation 
of HCMV infection during a follow-up of > 6 months post-vacci- 
nation. In this study, we show for the first time that a vaccination 
with HCMV pp65-peptide pulsed donor-derived Des can be safe- 
ly applied after SCT. Comparative studies will have to show 
whether De-vaccination enhances HCMV-specific immunere- 
constitution post allografting. 
36 
BRONCHOALVEOLAR LAVAGE (BAL) IN PATIENTS (PTS) WITH PUL- 
MONARY COMPLICATIONS UNDERGOING HEMATOPOIETIC PROGENI- 
TOR CELL TRANSPLANT (HPCT): A SINGLE CENTER EXPERIENCE 
Al, h3,aTzkav , S'J; Yagmz, ~I. 2, Lem, V2; Schwartz, B.2; Esm:yer, C), 
Bm'nhm't, C e; McGztirk, ff J; Belt, RJ I. Kansas Ci~ Cancer" Ce~ztevs, 
Ka*zsas Ci U, 3/10; 2. The C:aTwe*" bzstitute, Kmzsas City, MO. 
Fiberoptic bronchoscopy with BAL is a clinically safe and usefol 
diagnostic procedure in HPCT pts and is often used with pul- 
monary complications post transplant. We retrospectively 
reviewed our experience with BAL as a diagnostic tool in one hun- 
dred thirty-nine consecutive patients who underwent HPCT at 
our institution. From January 1, 2000 to December 31, 2001, 39 
(28%) HPCT patients underwent a total of 62 BAL procedures. 
The median age was 48 years (range 22-64), 57% were male. 
Twenty-eight pts underwent an allogeneic HPCT and 9 pts had 
an autologous HPCT. Diseases which indicated HPCT included 
leukemia (n=18), NHL (n=10), MIM (n=7), other (n-2). BAL fluid 
was analyzed by rapid viral antigen assay (Chemicon Internation- 
al&#61650; ) for RSV, adenovirus, influenza, and parainfluenza; 
and cytology, gram stain, silver stain for PCP and fungms, AFB 
stain, PCR for CMV, and bacterial, fungal and viral cultures. Indi- 
cations for BAL were driven by radiographic findings of pul- 
monary infiltrates/nodules (74%) or respiratory s anptoms (26%). 
No post-HPCT patient had pre-existing lung disease. All BAL 
procedures were well tolerated with no reported complications. In 
32 (52%) of the BAL the following infections were identified: 
CMV (n=8), (4 by viral culture, 4 by PCR), Candida glabrata 
(n=7), bacterial infections (n=5), RSV (n=4), HHV6/HSV (n=5), 
fungal infections (n=2), and EBV (n=I). Thirty (48%) of the BAL 
procedures yielded no infectious pulmonary etiology. The final 
clinical diagnoses in this group included: idiopathic pneumonitis 
(n=10), diffuse pulmonary hemorrhage (n=6), bronchiolitis oblit- 
erans (n=5), recurrent malignancy (n=l), and no diagnoses (n=8). 
The diagnostic yield of the BAL for identifying a specific infec- 
tious pulmonary process was 52%. We conclude that BAL is a safe 
and useful diagnostic tool in HPCT patients with puhnonary 
complications. 
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PULMONARY HYPERTENSION (PH) COMPLICATING ALLOGENEIC 
HEMAPOIETIC STEM CELL TRANSPLANT (HSCT) IN CHILDREN AND 
ADOLESCENTS 
Gilled', R.H); Qui~zo~zes, RS; Iv):, DJ; Al,mmz, S); ~lalcob:6 J.:; COL/, 
ft.2; Hild, E.2; Detevding, RJ 1. Unive1"sity of Colorado School f3/ledi- 
cilJe, Derive:, CO; 2. The Chikb'eT~ 's Hospital, Delzve~', CO. 
Puhnonary disease is a frequent cause of morbidity and mortality 
following allogeneic HSCT. After observing several patients who 
developed ifficulty with PH associated with non-infectious inter- 
stitial pneumonitis, we conducted a retrospective r view of the 
incidence and effects of puhnonary hypertension i all patients 
who underwent allogeneic HSCT at our center between January 
1994 and September 2002 (N=103). All echocardiograms, autop- 
sies (N=23) and lung biopsies (N=31) done in these 103 patients 
were evaluated. ECHO's were routinely done pre-HSCT, at 3, 6, 
12 and 24 months post HSCT, and when cardiopulmonary prob- 
lems occurred. PH was diagnosed when ECHO showed R ven- 
tricular pressure>40mm Hg, R ventricular dilation, and/or R ven- 
,tricular hypertrophy. Histologic diagnosis of PH on autopsy or 
lung biopsy required finding intimal nmscle proliferation in pul- 
monary arterioles. PH was detected post-HSCT in 20 of 103 
patients (19%). Diagnosis was by ECHO in 16 cases, autopsy in 2 
and lung biopsy in 2. Median age at HSCT in PH patients was 8y 
(range, 6m-24y). PH was first recognized at a median of 62 days 
post-HSCT (range, day 0 to +631). The HSCT indication in 
patients with PH was ALL (N=9), AML (4), CML (2), NHL (2), 
